Rigel Pharmaceuticals (RIGL) Net Income towards Common Stockholders (2010 - 2026)

Rigel Pharmaceuticals' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $8.7 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 24.39% year-over-year to $8.7 million in Q1 2026; TTM through Mar 2026 was $364.2 million, a 879.7% increase from a year earlier, with the FY2025 full-year figure at $367.0 million, up 1999.08% from the prior year.
• Net Income towards Common Stockholders slipped to $8.7 million in Q1 2026 per RIGL's latest filing, from $268.1 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $268.1 million in Q4 2025 and bottomed at -$27.4 million in Q1 2022.
• The 5-year median for Net Income towards Common Stockholders is $11000.0 (2023), against an average of $18.2 million.
• Across the five-year window, Net Income towards Common Stockholders slumped 169.48% in 2022 and surged 130272.73% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $1.4 million in 2022, then plunged by 99.21% to $11000.0 in 2023, then jumped by 130272.73% to $14.3 million in 2024, then surged by 1769.22% to $268.1 million in 2025, then plunged by 96.77% to $8.7 million in 2026.
• Per Business Quant, the three latest RIGL Net Income towards Common Stockholders figures stand at $8.7 million (Q1 2026), $268.1 million (Q4 2025), and $27.9 million (Q3 2025).